The stock has been on fire since September, but Stifel analyst Ruben Roy thinks there is still money to be made on Celestica (Celestica Stock Quote, Chart, News, Analysts, Financials NYSE:CLS).
The analyst says CLS may be partly driven by AI hype at the moment, but argues that something more long-term is afoot.
“While we have seen multiple re-rating as CLS has been identified as a beneficiary of AI infrastructure spend, we believe that we remain in the early stages of a long-tailed investment cycle,” he wrote. “Recent new HPS customer program wins would indicate that CLS continues to execute against this longer-term opportunity. We also expect gradual stabilization and improvement in the company’s Advanced Technology Solutions (ATS) segment as we progress through 2025.”
As reported by The Globe and Mail, Roy February 4th maintained his “Buy” rating and price target of (US) $140.00 on Celestica.
“We believe Celestica will continue to benefit from multiple expansion as the company continues to execute on adding specialized capabilities to serve the emerging needs of a broad and diverse customer base.” Roy added. “Believe that a focused and long, multi-year effort through investments in engineering capabilities, strategic manufacturing footprint and process innovation, Celestica has emerged as a key partner to leading U.S. hyperscaler customers. We expect Celestica to benefit, longer-term, from a market leadership position as AI infrastructure investments continue over the next several year.”
Ventum Capital Markets analyst Rob Goff lowered his price target on Alithya Group (Alithya Group Stock Quote, Chart, News, Analysts,… [Read More]
Roth Capital Markets analyst Scott Searle maintained a “Buy” rating and $22.00 12-month target on Arlo Technologies (Arlo Technologies Stock… [Read More]
DoubleDown Interactive (DoubleDown Interactive Stock Quote, Chart, News, Analysts, Financials NYSE:DDI) remains compelling according to Roth analyst Eric Handler, who… [Read More]
Research Capital analyst Andre Uddin maintained his “Buy” rating and C$5.55 target on Medexus Pharmaceuticals (Medexus Pharmaceuticals Stock Quote, Chart,… [Read More]
Ventum Capital Markets analyst Rob Goff raised his target on Calian Group (Calian Group Stock Quote, Chart, News, Analysts, Financials… [Read More]
Desjardins Securities analyst Benoit Poirier has raised his target on Bombardier (Bombardier Stock Quote, Chart, News, Analysts, Financials TSXV:BBD.B) after… [Read More]